https://doi.org/10.4081/reumatismo.2010.101

Safety of rituximab in rheumatoid arthritis

Vol. 62 No. 2 (2010)
Abstract Views: 1587
PDF: 961
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. Covelli
office@pagepress.org
P. Sarzi-Puttini
F. Atzeni
P. Macchioni
Patients with rheumatoid arthritis (RA) are at increased risk of manifestations such as serious infectious events (SIEs), malignancies and cardiovascular disease (1). Moreover, a long administration of drugs is required in this chronic disease, a condition that is responsible of a greater risk of side effects. As an example, there is an almost 2-fold greater risk on a SIE in patients with RA than in general population (2). Furthermore bacterial infection, one of the leading cause of morbidity and mortality in RA patients (3), is not an uncommon side effect of therapy. In addition, the use of corticosteroids, even at low doses (10 mg per day or less), utilized in approximately 65% of patients in randomized clinical trials is an important contributory factor to the increased prevalence of SIEs among RA patients (2, 4)...

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Covelli, M., Sarzi-Puttini, P., Atzeni, F., & Macchioni, P. (2010). Safety of rituximab in rheumatoid arthritis. Reumatismo, 62(2), 101–106. https://doi.org/10.4081/reumatismo.2010.101

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.